A TBA-benzothiazole-urea-sulfonate SSA with a similar structure to that of 3 has already been shown to exhibit a drug-like profile through initial in vitro assays consisting of plasma stability, mouse, rat and human microsomal stability, plasma protein binding and Caco-2 permeability. This was followed by in vivo pharmacokinetic analysis in mice. Here the TBA-benzothiazole-ureasulfonate SSA was administered intravenously and distribution of the TBA-benzothiazole-ureasulfonate SSA was measured in the lung, muscle and liver tissues. Due to the presence of a squaramide in 4 and 5, we also chose to investigate the DMPK properties of 5 to understand the implication of squaramide and carboxylate functionalities on the drug-like properties of SSAs. For experimental details and data, please see Section S5. These data show that the introduction of the carboxylate and squaramide functionalities into the SSA structure does not impact on the in vitro drug-like properties of the SSAs. However, these structural modifications do impact the SSA in vivo profile, increasing systemic clearance and volume of distribution versus a TBA-benzothiazole-urea-sulfonate SSA when the SSA is administered intravenously into the mouse.